Search research articles
Contact Us
Filters
Showing results (561-570 of 590) with videos related to
Page
of 59
Sort By:
The Lancet. Diabetes & Endocrinology
|
June 24, 2025
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Linong Ji, Leili Gao, Haibo Xue, et al.
BMJ Open Diabetes Research & Care
|
April 3, 2020
New clinical screening strategy to distinguish <i>HNF1A</i> variant-induced diabetes from young early-onset type 2 diabetes in a Chinese population
Yumin Ma, Siqian Gong, Xirui Wang, et al.
JAMA Ophthalmology
|
October 9, 2025
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial
Haiyang Zhang, Jing Sun, Yinwei Li, et al.
Cardiovascular Diabetology
|
February 24, 2026
From global guidelines for cardio-kidney-metabolic diseases management to national implementation: perspectives from the guideline workshop taskforce
Christoph Wanner, Francesco Cosentino, Katharine Barnard-Kelly, et al.
The Lancet. Diabetes & Endocrinology
|
May 9, 2018
Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
Dalong Zhu, Shenglian Gan, Yu Liu, et al.
The New England Journal of Medicine
|
June 8, 2026
Survodutide Once Weekly for the Treatment of Adults with Obesity
Carel W le Roux, Sean Wharton, Elena Startseva, et al.
Cardiovascular Diabetology
|
February 7, 2025
Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop
Katharine Barnard-Kelly, Tadej Battelino, Frank C Brosius, et al.
JAMA Cardiology
|
March 25, 2026
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial
Sharon L Mulvagh, Silvio E Inzucchi, Nikolaus Marx, et al.
Diabetes Care
|
June 8, 2026
Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial
Jelle M Beernink, Hiddo J L Heerspink, Andreas L Birkenfeld, et al.
Science Bulletin
|
January 19, 2023
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
Linong Ji, Weihong Song, Hui Fang, et al.
Page
of 59
Search research articles
Search
Showing results (561-570 of 590) with videos related to
Sort By:
Page
of 59
The Lancet. Diabetes & Endocrinology
|
June 24, 2025
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Linong Ji, Leili Gao, Haibo Xue, et al.
BMJ Open Diabetes Research & Care
|
April 3, 2020
New clinical screening strategy to distinguish <i>HNF1A</i> variant-induced diabetes from young early-onset type 2 diabetes in a Chinese population
Yumin Ma, Siqian Gong, Xirui Wang, et al.
JAMA Ophthalmology
|
October 9, 2025
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial
Haiyang Zhang, Jing Sun, Yinwei Li, et al.
Cardiovascular Diabetology
|
February 24, 2026
From global guidelines for cardio-kidney-metabolic diseases management to national implementation: perspectives from the guideline workshop taskforce
Christoph Wanner, Francesco Cosentino, Katharine Barnard-Kelly, et al.
The Lancet. Diabetes & Endocrinology
|
May 9, 2018
Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
Dalong Zhu, Shenglian Gan, Yu Liu, et al.
The New England Journal of Medicine
|
June 8, 2026
Survodutide Once Weekly for the Treatment of Adults with Obesity
Carel W le Roux, Sean Wharton, Elena Startseva, et al.
Cardiovascular Diabetology
|
February 7, 2025
Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop
Katharine Barnard-Kelly, Tadej Battelino, Frank C Brosius, et al.
JAMA Cardiology
|
March 25, 2026
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial
Sharon L Mulvagh, Silvio E Inzucchi, Nikolaus Marx, et al.
Diabetes Care
|
June 8, 2026
Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial
Jelle M Beernink, Hiddo J L Heerspink, Andreas L Birkenfeld, et al.
Science Bulletin
|
January 19, 2023
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
Linong Ji, Weihong Song, Hui Fang, et al.
Page
of 59